What tests do you offer?
Next Generation Sequencing (NGS) based
Although we offer a full range of services in order to best fit the varied needs of customers, our core test utilises NGS technology. This allows us to examine multiple genes simultaneously, thus gaining a better understanding of what may, or alternatively may not, be driving a patient’s cancer. This in turn gives the clinical care team a better chance of finding something that can help fight it.
Our current principal NGS test (MGP-4) is comprised of two components (click here for a general overview and here for specific details of exactly what is included) which have been developed and validated in-house (we are UKAS Accredited to ISO15189). One if these components sequences DNA isolated from the tumour, the other RNA, and collectively they are designed to help guide treatment decisions with specific targeted therapies (excludes PARP or immune Check Point inhibitors). For less common tumour types and/or those where targetable variants/processes may exist in genes beyond those included in our in-house NGS test, we can also facilitate pre-analytical assessment and specimen referrals on to our carefully selected partner organisations.
In additional to NGS based tests we also offer a range of other molecular diagnostic assays providing diagnostic, prognostic and treatment stratification related information. These include:
- Rapid single gene (BRAF, KRAS, NRAS & EGFR) analyses, for use in time-critical solid tumour cases.
- Endopredict (from Myriad Genetics), for use in breast cancer patients to assess the relative risks/benefits of post surgical chemotherapy.
- Micro-Satellite Instability (MSI) analysis, for use in assessing the likelihood of Lynch Syndrome and/or potential response to immune Check Point Inhibitor (CPI) therapy in certain tumours.
- MLH1 promoter methylation anaylsis, for use in conjunction with MSI, BRAF and/or immunohistochemistry to assess the likelihood of Lynch Syndrome.
Take a closer look at our tests, and read more about what they can tell you.
As we are constantly developing and validating new tests to support and expand the existing repertoire, make sure you watch this space!